1. Introduction {#sec1}
===============

Bladder cancer (BC)---the 11th most commonly diagnosed cancer worldwide \[[@B1]\]---presents in up to 80% of all patients either as a noninvasive papillary carcinoma (pTa) or as a carcinoma invading the submucosal connective tissue (pT1) \[[@B2], [@B3]\]. However, approximately 70% of these superficial tumors recur and up to a quarter even progress into muscle invasive bladder cancer (MIBC) \[[@B4]\]. Since close cystoscopic monitoring of recurrence and progression after initial transurethral resection of the tumor causes immense healthcare costs \[[@B5]\], accurate markers are needed in addition to clinicopathological factors \[[@B6]\] to individualize postoperative follow-up schedules \[[@B7]--[@B9]\]. Although numerous studies have evaluated the predictive value of different biomarkers in regard to progression of superficial bladder cancer \[[@B10]--[@B19]\], none of them has an established role in daily clinical practice.

CD73 (NT5E, ecto-5′-nucleotidase) is a glycosylphosphatidylinositol- (GPI-) anchored cell-surface enzyme that plays a crucial role in the purinergic signalling pathway by dephosphorylating AMP (adenosine monophosphate) into adenosine \[[@B20], [@B21]\]. Extracellular adenosine itself is involved in tumor immunoescape and invasion of tumor cells \[[@B22]\], while nonenzymatic functions of CD73 are related to cell adhesion and migration of tumor cells \[[@B23], [@B24]\].

CD73 expression has been investigated in many different cancer cell lines and human tumor biopsies so far and seems to play an important role in cancer development \[[@B20], [@B25], [@B26]\]. The role of CD73 in bladder BC is not well known and controversial \[[@B27]--[@B30]\]. Furthermore, neither larger expression studies of CD73 in BC biopsies nor studies investigating the predictive ability of this marker have been published so far. The aim of the present study is to evaluate the association between CD73 expression and tumor progression in a large cohort of patients with primary BC.

2. Material and Methods {#sec2}
=======================

Tissue microarrays (TMA) were constructed from 348 formalin-fixed, paraffin-embedded urothelial BC tissues from 174 patients as previously described \[[@B31]\]. Tumor samples were represented in duplicate tissue cores with a diameter of 1 mm. The collection of the specimens was performed by the Institute of Surgical Pathology, University Hospital, Zurich, Switzerland, between 1990 and 2006. The tissue samples in TMA represent a series of 174 consecutive (nonselected) primary urothelial bladder tumors consisting of 90 pTa, 68 pT1, and 16 ≥ pT2 tumors. A board-certified pathologist (Peter Wild) reevaluated the hematoxylin-and-eosin-stained slides of all specimens. Tumor stage and grade were assigned according to UICC and WHO criteria. Additionally, to analyse the immunoreactivity of CD73 in normal urothelium, eight slides were cut from formalin-fixed, paraffin-embedded urothelium of the bladder neck of patients without any history of urothelial dysplasia or BC.

Retrospective clinical follow-up data were available for all the 174 patients (100%). The median follow-up period for the entire cohort was 110.6 months ranging from 32.4 to 226.8 months. Unfortunately, a proper analysis of adjuvant bladder instillation therapy (BCG or chemotherapy) could not be performed due to missing data in about 50% of the patients. The TMA and its clinical cohort have been previously published \[[@B32]\]. Descriptive characteristics of the cohort are depicted in [Table 1](#tab1){ref-type="table"}. The study was approved by the Cantonal Scientific Ethics Committee Zurich (<http://www.kek.zh.ch>, approval number: StV-NR. 25/2007).

TMA was freshly cut and used on 3 *μ*m paraffin sections as described previously \[[@B33]\]. The immunohistochemical detection of CD73 on tissue samples was performed by use of Anti-NT5E rabbit polyclonal antibody from Sigma Chemical Company, Saint Louis, United States (dilution 1 : 500). Clone MIB-1 (dilution 1 : 50; Dako, Glostrup, Denmark) was used for the detection of Ki-67. Immunohistochemical studies utilised an avidin-biotin peroxidase method with a diaminobenzidine (DAB) chromogen. After antigen retrieval (microwave oven for 30 min at 250 W), immunohistochemistry was conducted using a NEXES autostainer (Ventana, Tucson, AZ, USA) following the manufacturer\'s instructions.

Two experienced pathologists (Lorenz Buser and Peter Wild) evaluated all slides. Membranous CD73 immunoreactivity in the basal layer was assessed by using a semiquantitative three-scale scoring system ranging from 0 to 2+ (score 0: no staining; score 1+: weak staining; score 2+: strong staining).

In the situation of observing different staining intensities between the duplicate tissue cores, the core with more representative tumor tissue was chosen. If both duplicate tissue cores with different staining intensities demonstrate a comparable amount of representative tumor tissue, the intensity of the core with more homogenous staining intensity was selected. Immunoreactivity of CD73 was dichotomized for analytical purposes into a CD73 low-expression group (containing scores 0 and 1+) and a CD73 high-expression group (containing score 2+). The percentage of Ki-67 positive cells of each specimen was determined as described previously \[[@B34]\]. More than 10% of positive tumor cells were defined as a high Ki-67 labelling index \[[@B35]\].

Statistical analyses were performed with SPSS version 22 (IBM, Armonk, USA). *p* values \< 0.05 were considered as statistically significant. The statistical associations between clinicopathological and immunohistochemical data were analysed by using contingency tables together with Fisher\'s exact test (2-sided) for all binary variables and the Chi-square test (2-sided) for all other nominal variables. In the subgroup of nonmuscle-invasive bladder cancer (NMIBC, pTa and pT1), progression-free survival (PFS) was evaluated. Stage-shifts (from pTa to pT1-4 or from pT1 to pT2-4) or the detection of distant metastasis was considered as progression. The Kaplan-Meier method was used for plotting the PFS curves. Significant differences between the curves were analysed by using the two-sided log-rank test. Associations between clinicopathological/immunohistochemical data and PFS were evaluated by univariable and multivariable Cox regression. All significant variables in the univariable analysis were used in the multivariable model.

3. Results {#sec3}
==========

All 174 (100%) tumor samples could be evaluated for CD73 immunoreactivity. CD73 showed a membranous immunoreactivity, which was much more pronounced in the basal layer than in the other tumor cells. Further, a faint and inhomogeneous cytoplasmatic staining was observed in most of the cases with positive membranous staining. In order to allow a distinct evaluation, only membranous CD73 immunoreactivity in the basal layer was assessed. [Figure 1](#fig1){ref-type="fig"} shows representative examples from our TMA for each staining score ranging from 0 to 2+.

A strong expression of CD73 (score 2+) was found in 46 of 174 patients (26.4%), whereas in 48 patients (27.6%) a weak immunoreactivity (score 1+) was detected. Finally, 80 patients (46%) showed no CD73 staining. The distribution of the dichotomized staining intensities of CD73 and Ki-67 are shown in [Table 1](#tab1){ref-type="table"}. Additionally, we investigated 8 samples of normal urothelium (Supplementary Figures S1A--F in Supplementary Material available online at <http://dx.doi.org/10.1155/2015/785461>) of individuals without any history of urothelial dysplasia or carcinoma. We observed a weak and inhomogeneous expression of CD73 in the cytoplasm and cell membrane, which was more pronounced in the basal layer in 4 out of 6 cases (Supplementary Figures S1A--C, F).

[Table 2](#tab2){ref-type="table"} shows the associations between CD73 staining patterns and clinicopathological parameters (stage, grade, adjacent carcinoma in situ, multiplicity, growth pattern, and Ki-67) of the tumors. High CD73 expression is associated with lower stage (*p* = 0.006), lower grade (WHO 2004, *p* = 0.014), less adjacent carcinoma in situ (*p* = 0.007) and lower Ki-67 expression (*p* = 0.008). Contingency table analysis for the Ki-67 labelling index and the clinicopathological characteristics have been previously published \[[@B32]\] and showed a significant correlation (*p* \< 0.05) with all clinicopathological characteristics except for tumor multiplicity.

158 out of 174 patients (90.8%) underwent TUR for a primary pTa or pT1 urothelial carcinoma of the bladder. This subgroup was followed for a median of 110.7 months (range: 32.4--245.9 months). In total, 22 patients (13.9%) showed a stage-shift. The median time to progression was 45.2 months ranging from 10.2 to 226.7 months. Kaplan-Meier analysis shows that patients within the subgroup of low CD73 expression have a significantly shorter PFS compared to the subgroup of high CD73 expression ([Figure 2](#fig2){ref-type="fig"}). The corresponding log-rank test renders a *p* value of 0.030. Growth pattern (*p* \< 0.001) and Ki-67 (*p* = 0.003) were also significantly associated with shorter PFS ([Table 3](#tab3){ref-type="table"}).

In univariable Cox regression ([Table 4](#tab4){ref-type="table"}), a high expression of CD73 reduces the rate of progression (hazard ratio, HR) by the factor of 0.228 (95% confidence interval \[CI\] ranging from 0.053 to 0.978; *p* = 0.047) compared to patients with a low expression of CD73. Of all other clinicopathologic parameters, growth pattern (HR = 7.634 \[2.717--21.740\]; *p* \< 0.001) and Ki-67 (HR = 3.356 \[1.429--7.874\]; *p* = 0.006) were significantly associated with reduced PFS. We performed multivariable Cox regression analysis for all significant predictors in univariable analysis, where CD73 did not remain a significant predictor. Only growth pattern remained an independent predictor for shorter PFS (HR = 3.891 \[1.245--12.195\]; *p* = 0.019).

4. Discussion {#sec4}
=============

This is the first study evaluating CD73 immunoreactivity in a large cohort of primary urothelial bladder carcinomas. We found that high CD73 expression is associated with lower stage, lower grade (WHO 2004), less adjacent carcinoma in situ and lower Ki-67 expression. In the subgroup of NMIBC (pTa and pT1), high CD73 immunoreactivity was associated with longer PFS in univariable Cox regression analysis but did not remain an independent predictor of longer PFS in multivariable Cox regression analysis.

Only a few studies have evaluated the role of CD73 in BC. Similar findings were reported by Wilson et al. who studied neoplastic transformed rodent bladders and detected a loss of CD73 after cancerous transformation \[[@B29]\]. A study using two human bladder cancer cell lines found a CD73 activity in the higher grade cell line of about five times as high as in the lower grade cell line \[[@B27]\]. Rockenbach et al. induced bladder cancer in mice and detected a higher expression of CD73 in the cancerous tissue \[[@B30]\]. One study evaluated CD73 enzyme activity in 36 human bladder cancer biopsies and 9 noncancerous bladder biopsies \[[@B28]\]. CD73 enzyme activity was comparable in BC and in normal urothelial tissue. However, contrary to our work, no follow-up data was reported on BC patients.

Several studies have investigated CD73 immunohistochemistry in other solid tumors. Interestingly, similar results have been reported for gynaecologic neoplasias: Oh et al. investigated 167 epithelial ovarian carcinomas and found associations between overexpression of CD73 and better prognosis, lower stage, and better differentiation \[[@B36]\]. Another study also assigning a favorable prognosis to elevated CD73 expression is the one of Supernat et al. that analysed 136 breast cancers (stages I--III) \[[@B37]\].

However, other investigations of CD73 in different solid tumors found contradictory results: CD73 has been reported as a disadvantageous prognostic or predictive factor, namely, in colorectal, gastric, gallbladder, prostate, and some forms of breast cancer \[[@B38]--[@B43]\].

Taken together, conflicting results have been published for the role of CD73 in solid tumors. Interestingly CD73 can be upregulated by several different mediators and conditions such as hypoxia \[[@B44], [@B45]\] and IFN-beta \[[@B46]\]. Hypoxia is a common characteristic of advanced cancers with poor progression while an increase in IFN-beta activates immunity against tumors \[[@B47]\]. Presence of hypoxia or IFN-beta in these tumors could partially explain the discrepancies. Furthermore, it is important to note that different tissues have very different enzymatic activity of CD73 \[[@B48]\]. This as well can potentially explain differences between different cancers.

In conclusion, our results are in contrast with the current proposed concepts from some authors, where overexpression of CD73 is considered as a disadvantageous factor in carcinogenesis \[[@B20], [@B25], [@B26]\]. In our study strong CD73 expression was associated with low-grade tumors, known for their good prognosis. Similar to our work, Oh and Rackley et al. could also detect firstly an inverse relationship between grading and expression of CD73 in epithelial ovarian carcinomas and prostate cancers, respectively, and secondly a direct relationship between expression of CD73 and advantageous prognosis \[[@B36], [@B49]\]. As in our work, strong CD73 expression was also proposed as a potential marker of good prognosis in breast cancer \[[@B37]\]. Very recently, a molecular biologic link between BC and breast cancer has been found, where a study identified two intrinsic, molecular subsets of high-grade BC, which have similar characteristics of subtypes of breast cancer \[[@B50]\]. The results of this work suggest that molecular characteristics of BC reflect many aspects of breast cancer. Since CD73 promotes the hydrolysis of AMP into adenosine and phosphate \[[@B20], [@B21]\], the results of our study could also be explained by the proapoptotic effect of adenosine postulated by several articles \[[@B51]--[@B53]\].

In our study, high CD73 expression is associated with lower stage and grade and therefore with low risk disease. However, we note that low CD73 expression is also present in a distinct amount of patients with pTa tumors (*n* = 57, 33%; see [Table 2](#tab2){ref-type="table"}). According to our results presented in [Table 2](#tab2){ref-type="table"}, it seems that strong expression of CD73 has good specificity (0.85) but low sensitivity (0.63) in the prediction of low risk (pTa) tumors.

There are limitations to our study. First, this is a retrospective, single-institution study. Second, information about adjuvant instillation therapy could not be evaluated. As tumor recurrence and progression is known to vary upon instillation therapy, it is an important missing aspect of this study. Also, the investigated study population has been collected over a long time period between 1990 and 2006 where clinical practice with respect to intravesical therapy has changed. Thus, this may have additionally influenced our study results. However, all patients had primary (nonrecurrent) tumors and a long follow-up period, which makes this study population nevertheless meaningful to study. Third, the low rate of MIBC patients has to be mentioned. Hence, no conclusion can be drawn for this group of tumors. Prospective studies with a higher proportion of MIBC are necessary to further evaluate the role of CD73 as a biomarker in BC. Furthermore---beside validation studies for the function of CD73 as a biomarker in BC---more research investigating the role of CD73 as a possible therapeutic target is warranted.

5. Conclusion {#sec5}
=============

High expression of CD73 is observed in BC patients with favorable pathological features. In NMIBC, high CD73 expression was additionally associated with good prognosis. Besides clinical and pathological parameters, detection of strong CD73 expression in BC may help to stratify patients into a low risk group. Further studies are warranted to confirm this hypothesis.
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###### 

Supplemental Figure 1: Normal urothelium (A-F) including von Brunn\'s nests (E-F) showing a weak and inhomogeneous, partly cytoplasmic and partly membranous immunoreactivity of CD73. The expression of CD73 is slightly accentuated in the basal layer in 4 out of 6 cases (A-C, F).
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![Immunohistochemical staining pattern of CD73. CD73 shows a distinct membranous immunoreactivity with pronounced intensity in the basal layer. Representative examples of score 0 (a), 1+ (b), and 2+ (c) are depicted.](DM2015-785461.001){#fig1}

![Kaplan-Meier analysis for progression-free survival comparing high and low CD73 expression. The log-rank test was used for the detection of statistical significance.](DM2015-785461.002){#fig2}

###### 

Patient and tumor characteristics and results of immunohistochemical analyses.

  Variable                                                Categorization   *n* analyzable^a^   \%
  ------------------------------------------------------- ---------------- ------------------- ------
  Clinicopathologic data                                                                       
  Age at diagnosis (median, range): 69.5 years (32--92)   \<70 years       87                  50.0
  ≥70 years                                               87               50.0                
  Sex                                                     Female           43                  24.7
  Male                                                    131              75.3                
  Tumor stage (WHO 1973^b^)                               pTa              90                  51.7
  pT1                                                     68               39.1                
  pT2                                                     13               7.5                 
  pT3                                                     2                1.1                 
  pT4                                                     1                0.6                 
  Histologic grade (WHO 1973^b^)                          G1               44                  25.3
  G2                                                      87               50.0                
  G3                                                      43               24.7                
  Histologic grade (WHO 2004^c^)                          Low grade        101                 58.0
  High grade                                              73               42.0                
  Adjacent carcinoma in situ                              No               158                 90.8
  Yes                                                     16               9.2                 
  Multiplicity                                            Solitary         124                 71.3
  Multifocal                                              50               28.7                
  Growth pattern                                          Papillary        159                 91.4
  Solid                                                   15               8.6                 
                                                                                               
  Immunohistochemistry (IHC)                                                                   
  CD73                                                    Score 0          80                  46.0
  Score 1+                                                48               27.6                
  Score 2+                                                46               26.4                
  Ki-67 labelling index                                   ≤10%             108                 62.1
  \>10%                                                   66               37.9                

^a^All patients.

^b^Staging and grading according to the 1973 WHO classification system.

^c^Staging and grading according to the 2004 WHO classification system.

###### 

Comparison of the immunohistochemical markers with pathologic characteristics (*n* = 174).

  Variable                         Categorization   CD73 expression        
  -------------------------------- ---------------- ----------------- ---- -----------
  Tumor stage (WHO 1973)^a^        pTa              57                33   **0.006**
  pT1                              57               11                     
  pT2                              12               1                      
  pT3                              2                0                      
  pT4                              0                1                      
  Histologic grade (WHO 1973)^a^   G1               31                13   0.100
  G2                               60               27                     
  G3                               37               6                      
  Histologic grade (WHO 2004)^b^   Low grade        67                34   **0.014**
  High grade                       61               12                     
  Adjacent carcinoma in situ^b^    No               112               46   **0.007**
  Yes                              16               0                      
  Multiplicity^b^                  Solitary         87                37   0.130
  Multifocal                       41               9                      
  Growth pattern^b^                Papillary        115               44   0.359
  Solid                            13               2                      
                                                                           
  Immunohistochemistry                                                     
  Ki-67 labelling index            ≤10%             72                36   **0.008**
  \>10%                            56               10                     

^a^Chi-square Pearson (2-sided); bold face representing *p* values \<0.05.

^b^Fisher\'s exact test (2-sided); bold face representing *p* values \<0.05.

###### 

Analysis of factors for tumor progression.

  Variable                         Categorization   Tumor progression (TP)        
  -------------------------------- ---------------- ------------------------ ---- --------------
  Pathologic data                                                                 
  Tumor stage (WHO 1973^c^)        pTa              90                       10   0.360
  pT1                              68               12                            
  Histologic grade (WHO 1973^c^)   G1               44                       3    0.085
  G2                               86               12                            
  G3                               28               7                             
  Histologic grade (WHO 2004^d^)   Low grade        99                       10   0.083
  High grade                       59               12                            
  Adjacent carcinoma in situ       No               146                      20   0.545
  Yes                              12               2                             
  Multifocality                    Unifocal tumor   115                      15   0.465
  Multifocal tumor                 43               7                             
  Growth pattern                   Papillary        151                      17   **\<0.0001**
  Solid                            7                5                             
                                                                                  
  Immunohistochemistry                                                            
  CD73                             Score 0 or 1+    114                      20   **0.030**
  Score 2+                         44               2                             
  Ki-67 labelling index            ≤10%             106                      9    **0.003**
  \>10%                            52               13                            

^a^Only primary pTa and pT1 tumors are included.

^b^Log-rank test (2-sided); bold face representing *p* values \<0.05.

^c^Staging and grading according to the 1973 WHO classification system.

^d^Staging and grading according to the 2004 WHO classification system.

###### 

Regression analysis.

  Variable (categorization)                 Univariable analysis   Multivariable analysis                                                   
  ----------------------------------------- ---------------------- ------------------------ -------- ------------- ------- ------- -------- -----------
  Tumor stage (pTa versus pT1)              1.481                  0.635                    3.454    0.363                                   
  Histologic grade (WHO 2004^a^)            2.070                  0.894                    4.808    0.090                                   
  Adjacent carcinoma in situ                1.563                  0.363                    6.711    0.549                                   
  Multifocality                             1.401                  0.565                    3.472    0.467                                   
  Growth pattern (papillary versus solid)   7.634                  2.717                    21.740   **\<0.001**   3.891   1.245   12.195   **0.019**
  CD73                                      0.228                  0.053                    0.978    **0.047**     0.319   0.072   1.408    0.132
  Ki-67                                     3.356                  1.429                    7.874    **0.006**     2.222   0.873   5.650    0.094

^a^Staging and grading according to the 2004 WHO classification system.
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